摘要
目的基于整合药理学,研究当归抗动脉粥样硬化(Atherosderosis,AS)的作用机制。方法借助中药整合药理学平台(TCMIP V2.0),预测分析当归抗动脉粥样硬化的机制及其药效物质基础。结果当归抗动脉粥样硬化的17种有效成分,直接或间接作用于PPARG(过氧化酶体增殖物激活受体)、APOE(载脂蛋白E)、卵磷脂胆固醇酰基转移酶(LCAT)、炎性趋化因子(CCL2)、基质金属蛋白酶9(MMP9)、MTTP(微粒体三酰甘油转移蛋白)等26个核心药靶,这些药靶作用涉及胆固醇跨膜转运、胆固醇酯代谢、炎症反应、脂质氧化修饰、PPARα活性基因的表达等10条主要调控通路。结论可预测当归中部分有机酸和挥发油成分主要通过PPARG、MTTP靶标作用炎症及脂质代谢通路对抗AS的发生。
Objective To study the anti-atherosclerosis(AS)mechanism of Angelica based on integrated pharmacology.Methods With TCMIP V2.0,the mechanism of anti-atherosclerotic effect of Angelica sinensis was predicted and analyzed.Results The 17 active components of Angelica had direct or indirect effects on twenty-six key drug targets,including PPARG,apoE,LCAT,CCL2,MMP9 and MTTP involving ten major regulatory pathways,such as cholesterol transmembrane transportation,cholesterol ester metabolism,inflammatory response,lipid oxidation modification,and PPARαactive gene expression.Conclusion It can be predicted that some organic acids and volatile oil components in Angelica can act on inflammation and lipid metabolism pathway through PPARG and MTTP to fight against AS.
作者
方欢乐
张慧
陶炎炎
李瑶窈
陈衍斌
FANG Huan-le;ZHANG Hui;TAO Yan-yan;LI Yao-yao;CHEN Yan-bin(Medical College of Xi′an Peihua University,Xi′an 710125,China;Scientific Research Department of Shaanxi Step Pharmaceutical Co.,Ltd,Xi′an 710075,China)
出处
《实用药物与临床》
CAS
2021年第2期122-127,共6页
Practical Pharmacy and Clinical Remedies
基金
陕西省重点研发计划项目(S2018-YF-YBSF-0010)
陕西省大学生创新创业项目(S201911400012)
咸阳市重大科技专项计划项目(2018K01-47)。
关键词
当归
动脉粥样硬化
网络药理学
物质基础
分子机制
Angelica
Atherosclerosis
Network pharmacology
Material basis
Molecular mechanism
